Home  Contact Us
  Follow Us On:
 
Search:
Advertising Advertising Free Newsletter Free E-Newsletter
NEWS

China reports 2 local cases
Published on: 2021-11-25
Share to
User Rating: / 0
PoorBest 

Chinese Covid-19 developers will kick off the country’s first clinical trial of using a home-grown mRNA vaccine as a booster shot to protect against Covid-19.
 

Walvax Biotechnology Co. and partner Suzhou Abogen Biosciences will test the safety and efficacy of their jointly developed mRNA vaccine, known as ARCoV-005, as a reinforcement shot for people fully inoculated with China’s widely used inactivated-virus vaccines, according to a filing published Wednesday by Walvax in the country’s online clinic trial database.
 

The Phase 3b clinical trial of the shot will start Thursday in Liuzhou, southwest China’s Guangxi region, and will run until Dec. 31. The trial aims to recruit 2,000 people above age 18 for the tests.
 

The Chinese mainland on Wednesday reported two new locally transmitted COVID-19 cases, both of which were reported in Yunnan Province, the National Health Commission said in its daily report on Thursday.
 

Wednesday also saw reports of 22 imported cases in nine provincial-level regions, said the commission.
 

No new deaths related to COVID-19 were reported on Wednesday, said the commission.
 

mRNA疫苗加强针即将临床试验

国内疫苗加强针“混打”研究快速推进,mRNA和重组蛋白两种技术路线均获进展。11月24日,沃森生物在中国临床试验注册中心网站上传了其mRNA疫苗作为加强针的临床试验信息。据其披露,受试者的招募将于11月25日开始。
 

昨日新增本土确诊病例2例,均在云南

11月24日0—24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增确诊病例24例。其中境外输入病例22例(上海4例,广东4例,广西4例,云南3例,山东2例,陕西2例,吉林1例,福建1例,四川1例);本土病例2例(均在云南德宏傣族景颇族自治州)。无新增死亡病例。新增疑似病例1例,为境外输入病例(在上海)。

Comments (0)Add Comment

Write comment

security code
Write the displayed characters


busy
    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2021 BusinessTianjin.com. All rights reserved.